Neoantigen-pulsed dendritic cells present peptides on HLA I/II to prime neoantigen-specific T cells; the activated CTLs then kill tumor cells presenting the neoantigen–HLA I complexes via perforin/granzyme. Dendritic cells expressing HLA class I are not directly targeted or killed by the therapy.